Skip to main content

Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?

Voriconazole is a first-line agent for treatment of systemic mycotic infections. However, intravenous use is contraindicated in patients with creatinine clearance <50 ml/minute because of accumulation of the toxic vehicle sulfobutylether-beta-cyclodextrin sodium [1, 2]. In a recent issue of Critical Care, Kiser and colleagues furnished convincing pharmacological evidence that sulfobutylether-beta-cyclodextrin sodium but not voriconazole was effectively removed by continuous veno-venous hemofiltration (CVVH). They concluded that standard intravenous voriconazole doses could be safely used when patients were placed under continuous renal replacement therapy [3].

We acknowledge the clinical relevance of this study but advocate a more balanced appraisal of the results. First, Kiser and colleagues applied CVVH doses ranging from approximately 25 to 75 ml/kg/hour in a small group of patients. This approach might introduce significant difference in substance elimination and does not conform to routinely used CVVH doses. Second, the study showed that sulfobutylether-beta-cyclodextrin sodium, being a middle molecular weight substance, was highly and dose-dependently eliminated by convection. However, diffusion-based continuous renal replacement therapy arguably will produce equally effective elimination. Third, if CVVH is performed without high flux or high cutoff membranes, convective capacity may rapidly falter due to a decrease in membrane porosity. This can be avoided by using regional citrate anticoagulation, which was not applied in this study.

Therefore, we recommend using CVVH (to privilege convective drug elimination) at a dose of 35 ml/kg/hour (to assure a minimal delivered dose of 25 ml/kg/hour) under regional citrate anticoagulation (to consolidate filter function) for permitting safe and adequate intravenous voriconazole treatment.

Abbreviations

CVVH:

continuous veno-venous hemofiltration

References

  1. 1.

    von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6.

    Article  Google Scholar 

  2. 2.

    Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99:3291–301.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19:32.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Patrick M Honore.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PMH and HDS designed the paper. All authors participated in writing the paper. All authors read and approved the final manuscript.

See related research by Kiser et al., http://ccforum.com/content/19/1/32

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Jacobs, R., Hendrickx, I. et al. Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?. Crit Care 19, 234 (2015). https://doi.org/10.1186/s13054-015-0946-1

Download citation

Keywords

  • Voriconazole
  • Continuous Renal Replacement Therapy
  • Filter Function
  • Pharmacological Evidence
  • Cutoff Membrane